Paul, Weiss, Goodwin, Cooley, Morrison & Foerster advised on Johnson & Johnson’s $3.3 billion acquisition of Ollin Biosciences.
Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for up to approximately $1.1 billion in additional regulatory and commercial milestone payments.
Paul, Weiss is advising Ollin Biosciences, Inc. on the acquisition.
The team is led by Corporate Partner Benjamin Goodchild; Executive Compensation Partner Matthew Friestedt and Counsel Annie Anderson; Antitrust Partners Jesse Solomon, Lauren O’Brien and Todd Hahn; Intellectual Property Partner Ian Edvalson and Counsel Sean Kwak; Tax Partner Jim Cole; and Litigation Partners Geoffrey Chepiga and Blake Rohrbacher, and Counsel Audrey Paquet.
Goodwin Procter is providing advice on corporate matters to Ollin Biosciences.
Cooley acted as legal counsel on intellectual property matters to Ollin Biosciences.
The team was led by Mika Reiner Mayer and Nitasha Bennett.
Morrison & Foerster is also advising Ollin Biosciences on intellectual property matters.